2[1]Available at http://www.nybloodcenter.org/index.jsp? sid0= 7
3[2]Dodd RY,Notari EP 4th,Stramer SL.Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population[J].Transfusion,2002,42(8):975
4[3]Soldan K,Barbara JA,Ramsay ME,et al.Estimation of the risk of hepatitis B virus,hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England,1993～2001[J].Vox Sang,2003,84(4):274
5[4]Mbanya D,Binam F,Kaptue L.Transfusion outcome in a resource-limited setting of Cameroon:a five-year evaluation[J].Int J Infect Dis,2001,5(2):70
6[5]Available at http://www.who.int/bloodsafety/gcbs/en/
7[6]Allain JP.Transfusion risks of yesterday and of today[J].Transfus Clin Biol,2003,10(1):1
8[7]Klein HG.Pathogen inactivation technology:cleansing the blood supply[J].J Intern Med,2005,257(3):224
9[8]Barbara JA.The rationale for pathogen-inactivation treatment of blood components[J].Int J Hematol,2004,80(4):311
